William Blair Weighs in on Envista's Q4 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST - Free Report) - Analysts at William Blair boosted their Q4 2025 earnings estimates for Envista in a report issued on Thursday, February 6th. William Blair analyst B. Vazquez now expects that the company will earn $0.34 per share for the quarter, up from their prior forecast of $0.33. The consensus estimate for Envista's current full-year earnings is $1.06 per share. William Blair also issued estimates for Envista's Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.24 EPS and Q3 2026 earnings at $0.23 EPS.

A number of other equities research analysts also recently issued reports on NVST. Stifel Nicolaus upped their price objective on Envista from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Wednesday, October 23rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a research note on Thursday, February 6th. Mizuho began coverage on Envista in a report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 price objective for the company. Wells Fargo & Company lifted their price target on Envista from $20.00 to $21.00 and gave the company an "equal weight" rating in a report on Thursday, February 6th. Finally, Robert W. Baird increased their price objective on Envista from $17.00 to $22.00 and gave the company a "neutral" rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $20.21.

Envista Price Performance

NVST stock traded down $0.26 during midday trading on Friday, hitting $20.97. The company's stock had a trading volume of 664,114 shares, compared to its average volume of 2,221,635. Envista has a 12 month low of $15.15 and a 12 month high of $23.06. The company has a 50 day moving average of $19.91 and a two-hundred day moving average of $19.23. The company has a quick ratio of 1.77, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of -3.23, a price-to-earnings-growth ratio of 2.06 and a beta of 1.34.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in shares of Envista during the fourth quarter worth about $691,000. Teacher Retirement System of Texas acquired a new stake in Envista in the fourth quarter valued at approximately $1,138,000. Chesapeake Capital Corp IL purchased a new position in shares of Envista in the fourth quarter valued at $216,000. Xponance Inc. grew its holdings in Envista by 5.8% during the 4th quarter. Xponance Inc. now owns 19,726 shares of the company's stock valued at $381,000 after purchasing an additional 1,077 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in shares of Envista by 88.9% in the fourth quarter. Royce & Associates LP now owns 526,985 shares of the company's stock worth $10,166,000 after acquiring an additional 248,081 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.